BioSpace News Archive

-Introduction to JanOne scientific team -Strategy for upcoming planned Phase 2b trial of JAN101 -Business development updates, including planned COVID-19 treatment study and focus on commercialization and production capabilities [21-August-2020] LAS VEGAS , Aug. 21, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing tre

Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a non-dilutive debt financing for ne

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF; PDDPF) today announces that it has begun trading on the OTCQX ® Best Market under the new ticker “MEDXF,” effective August 20, 2020. Medexus Pharmaceuticals Inc was upgraded to OTCQX from the OTCQB ® Venture Market on August 4, 2020. Medexus Pharmaceuticals Inc. has changed its ticker symbol from “PDDPF” to “MEDXF” and began trading yesterday on OTCQX under the

Bioinsider, leading virtual meeting venue for communication among the scientific, policymaker and business communities, has opened registration for its upcoming virtual meeting ‘Therapeutic Pipeline for COVID-19’ on September 17, 2020.

Tosk, Inc. announced today the release of a new video describing the company’s work and proprietary technology intended to transform the treatment of cancer and other diseases.

Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced it has commenced an underwritten public offering of shares of its common stock.

Evofem Biosciences, Inc., a commercial-stage biopharmaceutical company, announced that on August 18, the Compensation Committee of the Company’s Board of Directors approved the grant to 60 new employees of non-qualified stock option awards to purchase an aggregate of 319,200 shares of common stock.